Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Investing Activities (2016 - 2025)

Protalix BioTherapeutics has reported Cash from Investing Activities over the past 16 years, most recently at -$1.1 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at -$1.1 million for Q4 2025, up 92.74% from a year ago — trailing twelve months through Dec 2025 was -$2.4 million (down 156.05% YoY), and the annual figure for FY2025 was -$2.4 million, down 156.05%.
  • Cash from Investing Activities for Q4 2025 was -$1.1 million at Protalix BioTherapeutics, down from -$504000.0 in the prior quarter.
  • Over the last five years, Cash from Investing Activities for PLX hit a ceiling of $37.4 million in Q4 2021 and a floor of -$30.7 million in Q1 2021.
  • Median Cash from Investing Activities over the past 5 years was -$267000.0 (2023), compared with a mean of -$48500.0.
  • Biggest five-year swings in Cash from Investing Activities: surged 2913.43% in 2021 and later crashed 4379.53% in 2024.
  • Protalix BioTherapeutics' Cash from Investing Activities stood at $37.4 million in 2021, then tumbled by 86.77% to $5.0 million in 2022, then tumbled by 106.9% to -$342000.0 in 2023, then crashed by 4379.53% to -$15.3 million in 2024, then skyrocketed by 92.74% to -$1.1 million in 2025.
  • The last three reported values for Cash from Investing Activities were -$1.1 million (Q4 2025), -$504000.0 (Q3 2025), and -$438000.0 (Q2 2025) per Business Quant data.